Treatment with abelacimab could result in potential cost-savings of $50,000 over a lifetime per patient basis and higher quality-adjusted life years in atrial fibrillation patients at a high risk of ...

The novel factor XI/XIa inhibitor abelacimab, being studied in the AZALEA-TIMI 71 trial, lowered a composite of major and clinically relevant nonmajor bleeding compared with rivaroxaban in patients ...

Lower levels of free factor XI and fewer bleeding events seen in patients with atrial fibrillation at moderate-to-high risk for stroke. (HealthDay News) — Subcutaneous injection of abelacimab results ...

In patients with AF, abelacimab, compared with rivaroxaban, is associated with decreased bleeding across multiple bleeding risk categories. Abelacimab is associated with reduced bleeding compared with ...

TCTMD reported in-depth on the AZALEA-TIMI 71 trial, November 12, 2023, at the American Heart Association (AHA) 2023 meeting. The full manuscript was subsequently published in The New England Journal ...

Christian T. Ruff, MD, MPH, of Brigham and Women's Hospital, discusses new data comparing abelacimab with rivaroxaban in patients with atrial fibrillation presented at the American College of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In patients with AF requiring anticoagulation, the ...

Please provide your email address to receive an email when new articles are posted on . Patients with AF taking abelacimab had very low rates of bleeding when undergoing invasive procedures. The ...

Abelacimab, an experimental anti-clotting drug, was effective at lowering bleeding in people with atrial fibrillation (A-Fib) who were at risk of having a stroke compared with a competing drug, ...

Favorable bleeding outcomes related to abelacimab have positioned the medication as a potential game changer in the treatment of atrial fibrillation. One of the core results from AZALEA-TIMI 71 was ...

The phase 3 MAGNOLIA trial will assess whether abelacimab can prevent venous thromboembolism recurrence in patients with gastrointestinal or genitourinary cancers. Recruitment has started for a phase ...

The median reduction in free factor XI levels was 99% and 97% with abelacimab at a dose of 150mg and 90mg, respectively, at 3 months. (HealthDay News) — Subcutaneous injection of abelacimab results in ...